Nurix Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 4,356 shares of common stock on August 5, 2026 for $25.00 per share.
NASDAQ
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 4,111 shares of common stock on August 4, 2026.
NASDAQ
Houte Hans Van, Chief Financial Officer of Nurix Therapeutics, Inc., sold 4,761 shares of common stock on August 4, 2026.
NASDAQ
Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., sold 16,589 shares of common stock on August 3, 2026 for $23.05 per share.
NASDAQ
Houte Hans Van, Chief Financial Officer of Nurix Therapeutics, Inc., sold 2,845 shares of common stock on July 30, 2026 for $23.38 per share.
NASDAQ
Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., sold 3,847 shares of common stock on July 30, 2026 for $23.38 per share.
NASDAQ
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 3,847 shares of common stock on July 30, 2026 for $23.38 per share.
NASDAQ
Nurix Therapeutics Chief Legal Officer Christine Ring executed a series of stock transactions on July 2, 2026, under a pre-established Rule 10b5-1 trading plan.
NASDAQ
Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc., sold 5,394 shares of common stock on June 25, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
NASDAQ
Nurix Therapeutics Chief Legal Officer Christine Ring reported transactions involving company stock, including acquisitions and sales under a Rule 10b5-1 trading plan.
NASDAQ
Chief Legal Officer Christine Ring exercised options and sold shares of Nurix Therapeutics under a Rule 10b5-1 plan.
NASDAQ
Director Paul M. Silva was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Edward C. Saltzman was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard compensation.
NASDAQ
Director Judith A. Reinsdorf was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of a standard equity award.
NASDAQ
Director David L. Lacey was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Anil Kapur was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Roger D. Dansey was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Roy D. Baynes was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard compensation.
NASDAQ
Director Julia P. Gregory was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Nurix Therapeutics CFO Hans van Houte sold 14,055 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Chief Legal Officer Christine Ring sold 8,148 shares of Nurix Therapeutics common stock via a 10b5-1 trading plan.
NASDAQ
Nurix Therapeutics Chief Legal Officer Christine Ring sold 5,394 shares of common stock under a pre-arranged trading plan.
NASDAQ
CFO Hans van Houte sold 2,388 shares of Nurix Therapeutics to satisfy tax obligations related to RSU vesting.
NASDAQ
Chief Legal Officer Christine Ring sold 3,214 shares of Nurix Therapeutics to satisfy tax obligations related to RSU vesting.
NASDAQ
Chief Scientific Officer Gwenn Hansen sold 3,214 shares of Nurix Therapeutics to satisfy tax obligations related to RSU vesting.
NASDAQ
Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., reported a sale of 8,148 shares of common stock on April 2, 2026, executed under a Rule 10b5-1 trading plan.
NASDAQ
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 8,148 shares of common stock for a weighted average price of $15.4385 under a pre-arranged 10b5-1 trading plan.
NASDAQ
Nurix Therapeutics' Chief Financial Officer, Hans van Houte, received significant equity awards, including stock options and restricted stock units, as part of his compensation.
NASDAQ
Nurix Therapeutics' Chief Legal Officer, Christine Ring, was granted 93,750 stock options and 42,875 restricted stock units.
NASDAQ
Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, was granted 93,750 employee stock options and 42,875 restricted stock units.